|Company Name:||J & K SCIENTIFIC LTD. |
|Product Name:||Rebeprazole sodium|
|Synonyms:||2-[[[4-(3-METHOXYPROPOXY)-3-METHYL-2-PYRIDINYL]METHYL]SULFINYL]-1H-BENZIMIDAZOLE, SODIUM SALT;2-[[[4-(3-METHOXYPROPOXY)-3-METHYLPYRIDIN-2-YL]METHYL]SULFINY]-1H-BENZIMIDAZOLE SODIUM SALT;rebeprazole sodium;sodium 2-[[4-(3-methoxypropoxy)-3-methyl-pyridin-2-yl]methylsulfinyl]benzoimidazole;SODIUM RABEPRAZOLE;PARIET;RABEPRAZOLE SODIUM;RABEPRAZOLE, SODIUM SALT|
|Product Categories:||Intermediates & Fine Chemicals;Pharmaceuticals;Rabeprazole|
|Rebeprazole sodium Chemical Properties|
|mp ||140-141°C dec.|
|storage temp. ||Hygroscopic, -20°C Freezer, Under Inert Atmosphere|
|Rebeprazole sodium Usage And Synthesis|
|Anti-ulcer drug||Rabeprazole sodium is a anti-ulcer disease drug belonging to proton pump inhibitor and is the sodium salt form of Rabeprazole. The Japanese company Eisai had successfully developed it for the first time with the trade name being “Bolite”. The function of the proton pump inhibitors is reducing the gastric acid secretion so that the lesion site can be stable in order to achieving the effect of curing gastric and duodenal ulcers and stomach-esophageal reflux disease. Clinically it is majorly used for the treatment of acid-related diseases such as stomach and duodenal ulcers, peptic ulcer, gastroesophageal reflux disease and zollinger-ellison syndrome.
Rabeprazole is a kind of benzimidazole-substituted compounds. It inhibits the secretion of gastric acid through forming bond with the cytoplasmic proton pump in the gastric cavity wall. This product can specifically inhibit the effect of the adenosine triphosphatase that is the key enzyme during the production of stomach acid. It has inhibitory effect on both basal gastric acid and the gastric acid secretion caused by the stimulation. |
Rabeprazole is white-yellowish-white powder with no odor and a molecular weight being 381.43. This product is highly soluble in water or methanol, also soluble in ethanol or ethyl acetate but almost insoluble in ether or ethane. This product does not exhibit optical activity, has hygroscopic effect. Its melting point is 225 ℃ and its partition coefficient at water/octane system of pH 7.0 is about 214. This product is light yellow film-coated tablets (enteric-coated tablets).
Adverse reactions and precautions: gastric cancer should be excluded after use of the drug. Adverse reactions include allergic reactions, palpitations, constipation, diarrhea, headache, edema, leukopenia, AST, ALT, total bilirubin and proteinuria. The combination of Rabeprazole sodium and digoxin can cause increased digoxin concentration. It can’t be taken simultaneously with antacids. Patients of history of drug allergy, cirrhosis, the elderly, pregnant and lactating women, children should take with caution.
The above information is edited by the chemicalbook of Dai Xiongfeng.
|Uses||It belongs to national second-class drug that can be used for the treatment of gastric ulcer. It can be used for the treatment of peptic ulcer, gastroesophageal reflux disease, zollinger-ellison syndrome and other diseases.
|Chemical Properties||White Crystalline Solid|
|Usage||anthelminthic, antiseptic, expectorant|
|Usage||antibacterial and antifungal agent effective against gram-positive and gram-negative bacteria, yeast and fungi|
|Usage||A partially reversible gastric proton pump inhibitor|
|Rebeprazole sodium Preparation Products And Raw materials|